Target Information

Target General Infomation
Target ID
T62241
Former ID
TTDI01796
Target Name
Interleukin-17 ligand
Gene Name
IL25
Synonyms
IL25
Target Type
Clinical Trial
Disease Psoriasis [ICD9: 696; ICD10: L40]
Function
Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of ICAM1/intracellular adhesion molecule 1 in fibroblasts.
BioChemical Class
Cytokine: interleukin
UniProt ID
Q9H293
Sequence
MRERPRLGEDSSLISLFLQVVAFLAMVMGTHTYSHWPSCCPSKGQDTSEELLRWSTVPVP
PLEPARPNRHPESCRASEDGPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQT
GSHMDPRGNSELLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG
Drugs and Mode of Action
Drug(s) ALX-0761 Drug Info Phase 1 Psoriasis [889400]
Modulator ALX-0761 Drug Info [889442]
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
WikiPathways TCR Signaling Pathway
Allograft Rejection
IL17 signaling pathway
References
Ref 889400ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Ref 889442Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.